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L-alanyl L-glutamateAbstract Objective: The objective of this study was to evaluate the efficacy of using alanine–
glutamine (Aln–Gln) dipeptide as a supplement to control diabetes in liver transplanted patients.
Patients and methods: Eighty patients aged >18 yr admitted to ICU after receiving right lobe
living donor liver transplantation (LDLT), had a previous history of diabetes or had a new onset
diabetes (NODM) were enrolled in this prospective randomized double blind study. Patients were
randomized into two groups and assigned to receive parenterally an equal dose of amino acids
either with alanyl-glutamine dipeptide in the dose of 0.5 g/kg/d (group AG) or without alanyl-
glutamine dipeptide (control group C). This regimen started at day 1 postoperative in diabetic
patients or when new onset diabetes has been diagnosed in non-diabetic and continued till day 9
with measuring the incidence of hyperglycemia, hyperglycemic episodes, total insulin requirements/
day, infectious episodes, ICU and hospital length of stay, and 6 month mortality rate.
Results: The hyperglycemic episodes were significantly less in AG group patients than in control
group patients (29 vs 38). Hyperglycemia requiring insulin therapy in AG group was significantly
less (22 vs 28 patients). Also those who required decreasing TPN requirements were significantly
lesser in the AG group (7 vs 11 patients). Insulin requirements per day in the AG group were sig-
nificantly lower (53 ± 11 vs 78 ± 9 IU). The number of episodes of nosocomial infection per
patient was lower in the AG group than in the control group (20 vs 28). The decrease in nosocomial
infections in patients receiving AG was related mainly to a decrease in the incidence of pneumonia
(7 vs 11). The ICU length of stay (LOS) was significantly lower in the AG group than in the control
group (7.81 ± 2.98 vs 10.43 ± 4.67 day)
Conclusion: Our study showed that using AG supplementation in liver transplanted patients who
have either a history of diabetes or NODM, reduces the insulin requirements, hyperglycemic
episodes, infectious events and ICU stay.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Diabetes is a common complication of liver transplantation
increasing the risk of infection and mortality. New onset dia-
betes (NODM) accounts for nearly 15% of liver transplant
recipients and a similar proportion of patients have diabetes
prior to transplant thus increasing the magnitude of the prob-
lem [1]. Diabetes may develop from either impaired glucose
tolerance, insulin resistance associated with impaired liver
function, or a result of corticosteroids treatment post trans-
plant [2]. A proper tight glycemic control reduces morbidity
and mortality and requires multiple therapies.
Glutamine (Gln) is the most abundant free amino acid in
the extracellular and intracellular compartments, accounts
for approximately 6% of bound amino acids [3], and plays
an important role as immune function regulator and modula-
tion of cell metabolism [4]. Gln enhances glucose-stimulated
insulin secretion via the metabolism of the gamma-glutamyl
cycle, glutathione synthesis and mitochondrial function [5].
In conditions of excessive organ or tissue demand of glutamine
during episodes of sepsis, after trauma, major surgery, and
other catabolic stress situations, endogenous glutamine
production may not be sufficient to meet the increased
requirements.
Several studies have shown that alanine–glutamine
(Aln–Gln) dipeptide added to parenteral formulas improves
nitrogen balance; increases protein synthesis; ameliorates
immune function; preserves intestinal barrier permeability;
and can reduce morbidity, length of stay, and mortality in
critically ill patients [6–8]. Furthermore, glutamine can modify
fatty acid oxidation and attenuates hyperglycemia and insulin
resistance [9].
The aim of this study was to evaluate the efficacy of using
Aln–Gln as a supplement to control diabetes in liver
transplanted patients.
2. Patients and methods
After obtaining institution ethical board approval and written
informed consent from patients, eighty patients were enrolled
to this randomized double blind prospective, controlled study
conducted between February 2012 and August 2015 in liver
transplant unit in Ain Shams University Specialized Hospital.
Patients included in the study were adults >18 years, admitted
to ICU after performing right lobe living donor liver trans-
plantation (LDLT), had a previous history of diabetes or
had a new onset diabetes (defined as symptoms of diabetes plus
casual plasma glucose P200 mg/dl or fasting plasma glucose
P126 mg/dl on more than 2 occasions) [10].
Preoperative exclusion criteria were persistent hemody-
namic failure (systolic blood pressure <80 mmHg), severe
renal insufficiency (serum creatinine level P2.8 mg/dl and
(or) creatinine clearance <40 ml/min), and severe or uncon-
trolled sepsis. The following criteria may lead to the exclusion
of a patient even after inclusion in the study period: necessity
to perform major non-scheduled procedures within the study
with subsequent total parenteral nutrition (TPN) discontinua-
tion for more than 24 h, intolerable or serious adverse event,
any inter-current disease likely to interfere with the study, or
withdrawal of patient’s consent.All patients were assessed and received the standard preop-
erative care for patients undergoing liver transplantation
according to our unit protocol. Standard anesthetic and surgi-
cal techniques for hepatic transplantation were performed by
the same anesthesia and surgical team who were blinded to
study medication. At the end of surgery patients were trans-
ferred to the ICU intubated and mechanically ventilated until
fully conscious, good muscle power together with the standard
acceptable ventilatory and hemodynamic parameters of wean-
ing. Demographic data were obtained including age, sex, BMI,
history of diabetes and APACHE P score [11]. Fluid adminis-
tration in intensive care unit was adjusted to maintain central
venous pressure approximately 5–8 cmH2O, mean arterial
pressure >70 mmHg, urine output >1 ml/kg per hour. All
patients received similar postoperative intensive care with a
routine double immunosuppressive regimen including corticos-
teroids, and FK506 (tacrolimus) or cyclosporine. Mycopheno-
late with basiliximab are used instead of using tacrolimus or
cyclosporine if serum creatinine rise after 48 hours.
Intravenous methyl-prednisolone 500 mg was given intra-
operative after declamping. Maintenance dosage of methyl-
prednisolone was 1 mg/kg, to be tapered rapidly over the next
7–10 days. Maintenance prednisone 0.25 mg/kg/d was contin-
ued for 3 months then steroid therapy was stopped. Cyclospor-
ine was used for immunosuppressive therapy for all patients
except hepato-cellular carcinoma (HCC) patients, and starting
dose tacrolimus 0.5 mg was used instead. Maintenance dosages
of tacrolimus were adjusted to maintain a level of 10–12 ng/mL
during the first 2 months. For cyclosporine maintenance
dosages to achieve trough levels of 150–250 ng/mL were pre-
scribed in the first 2 months. Mycophenolate was used postop-
erative in the presence of preoperative renal impairment (cr.cl.
40–60) or postoperative renal dysfunction (rise in serum crea-
tinine level >0.3 mg/dl in less than 48 h) instead of calcineurin
inhibitors. Basiliximab was also used (day 0 and day 4) in the
presence of preoperative renal impairment.
Postoperative prophylactic antibiotic treatment included
piperacillin-tazobactam and Metronidazole for 10 days. All
patients received sulfamethoxazole/trimethoprim for prophy-
laxis against Pneumocystis carinii on day five for 6 months.
Fluconazole for prophylaxis of fungal infection was used for
specific cases such as severely malnourished patients, pro-
longed treatment with antibiotic, fulminant hepatic failure,
preoperative diabetic patients, re-exploration for surgical
causes, biliary leak and small for size liver transplant.
This study began at day 1 postoperative in diabetic
patients or when new onset diabetes has been diagnosed in
non-diabetic patients. Partial TPN was started at day one as
the standard protocol in our ICU. Non-protein energy require-
ments were calculated using the usual body weight and set at
25 kcal/kg/d. Protein requirements were set at 0.25 g N/kg/d.
Patients were randomly assigned on a basis of 1:1 by means of
a computer program into two groups AG group and control
group. Protein + Ala–Gln and Protein containing TPN were
labeled identically and the two solutions were indistinguishable.
All patients, investigators, and coworkers were unaware of
treatment allocation and remained blinded to the treatment
allocation until the final statistical evaluation was completed.
Patients in the Ala–Gln AG group (40 patients) received
0.5 g/kg/d of Ala–Gln dipeptide (AG) (Dipeptiven, Fresenius
Kabi Spain, SA) plus 1.0 g/kg/d of a standard admixture of
Table 2 Patients characteristics and APACHE II at study
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patients) received 1.5 g/kg/d of the same standard amino acids
admixture. The calorie/nitrogen ratio and glucose–lipid ratio
were, respectively, set at 100 and 64/36. Vitamins, trace ele-
ments, and electrolytes were administered according to the usual
practice of our ICU. The Spanish Pharmacy Registry limits the
use of Ala–Gln dipeptide to a maximum of 9 days [12]. If
patients needed to be treated after 9 days with TPN, Ala–Gln
dipeptide was discontinued, and they received the admixture
of amino acids used in the control group.
Regular insulin administration was started if the blood glu-
cose level exceeds 150 mg/dl. Adjustments of the insulin dose
were based on measurements of the whole blood glucose in
undiluted arterial blood at 1- to 4-h intervals with a glucose
analyzer. The following protocol for tight glycemic control
was used: if the blood glucose exceeds 200 mg/dl despite an
insulin administration of a maximum of 10 IU during 3 con-
secutive hrs, the TPN infusion was decreased by 50%. If the
blood glucose exceeds 200 mg/dl, despite the 50% decrease
of TPN infusion with an insulin administration of 10 IU dur-
ing 3 consecutive hrs, the TPN infusion was stopped (when the
blood glucose is between 120 and 200 mg/dl, the TPN infusion
was started again). If after restarting, despite a maximal insulin
administration, the blood glucose exceeds 200 mg/dl during
3 h, the TPN was definitively stopped and patient is withdrawn
from the study. Hourly glycemia and the hourly insulin dose
were recorded at least 15 times a day (see Table 1).
2.1. Outcome assessment
The primary outcome was the incidence of hyperglycemia,
hyperglycemic episodes that require insulin infusion, and epi-
sodes with 50% decrease of TPN as well as insulin needs to
assess the effect of glutamine on insulin resistance. For hyper-
glycemia, only one episode was considered for each patient
even if hyperglycemia was prolonged for several days.
Secondary outcomes were the incidence of nosocomial
infections acquired throughout the stay in ICU in patients
who received at least 4 days of treatment.
Nosocomial pneumonia was defined as follows: new onset
of purulent sputum; change in character of sputum, respiratory
secretions, or suctioning requirements; or worsening gas
exchange (e.g., PaO2/FIO2 < 240, increasing O2 requirements,
or increased ventilation demand) plus two or more serial chest
radiographs with new or progressive and persistent infiltrates;
consolidation or cavitation; and at least one of the following
laboratory findings: positive growth in blood culture not
related to another source of infection, positive growth in cul-
ture of pleural fluid, positive quantitative culture from mini-
mally contaminated lower respiratory tract specimen (e.g.:
broncho-alveolar lavage or protected specimen brushing) orTable 1 Proposed insulin infusion method based on hourly
measurement of capillary blood glucose level [13].
Glucose level (mg/dl) Insulin infusion (IU/h)
151–200 1.5–2.0
201–250 2.5–3.0
251–300 3.5–4.0
>300 5.0–6.0>5% broncho-alveolar lavage obtained cells contain intracel-
lular bacteria on direct microscopic examination (e.g., Gram-
negative stain). Other nosocomial infections were defined
according to the Centers for Disease Control and Prevention
guidelines [14]. Two investigators blinded to the treatment
allocation validated the diagnosis of infection, and each
infection at each site was considered as a separate infectious
complication. Other secondary outcomes are length of ICU,
hospital stay and 6 month mortality rate.
2.2. Sample size calculation
Sample size calculation was based on a power of 80% in
detecting a 25% reduction in the occurrence of hyperglycemic
episodes when the significance level is a= 0.05 with two sided
testing and previous experience showing normally distributed
data. With equal allocation ratio, it was estimated that each
group would include 35 patients. We included 40 patients in
each group for possible dropouts.
2.3. Statistical analysis
Data were analyzed using Statistical Program for Social
Science (SPSS) version 18.0. Data were tested for normality
using Kolmogorov–Smirnov test. Quantitative data were
expressed as mean ± standard deviation (SD). Qualitative
data were expressed as frequency and percentage. The follow-
ing tests were done: Independent-samples t-test was used when
comparing between two means and Chi-square (X2) test or
Fisher exact test was used as appropriate in order to compare
proportions between two qualitative parameters. P-value <
0.05 was considered significant.
3. Results
Between February 2012 and August 2015, 80 patients who
underwent LDLT were enrolled in this study after admission
to the ICU. They were randomized into AG group (n= 40)
and control group C (n= 40). These patients either have a
previous history of diabetes (21 patients in control group vs
23 in AG group) with no significant difference between the
two groups or suffered from NODM (19 patients in control
group vs 17 in AG group) with no significant history between
the two groups. On admission, there were no significant differ-
ences between the two groups regarding patients’ characteris-
tics and severity of illness score (APACHE II) (Table 2).admission.
Group (C)
(n= 40)
Group (AG)
(n= 40)
P-value
Sex [M/F] 22/18 24/16 0.821
Age (years) 53 ± 6 55 ± 7 0.124
BMI (kg/m2) 26.0 ± 19 24.9 ± 2.6 0.061
History of DM 21 (52.5%) 23 (57.5%) 0.880
NODM 19 (47.5%) 17 (42.5%) 0.822
APACHE II 16 ± 4 15 ± 3 0.421
Data are presented as number, percent and mean ± SD.
Table 3 Incidence of hyperglycemia and total insulin requirements per day.
Group (C) (n= 40) Group (AG) (n= 40) P-value
Hyperglycemia episodes 38 (95%) 29 (72.5%) 0.013*
Requiring insulin 28 (73.68%) 22 (75.86%) 0.023*
Requiring insulin + TPN volume reduction 11 (28.95%) 7 (24.14%) 0.039*
Total insulin req. IU/day 78 ± 9 53 ± 11 <0.001*
Data are presented as number, percent and mean ± SD.
* p-Value < 0.05 significant difference.
Table 4 Adverse events.
Group (C)
(n= 40)
Group (AG)
(n= 40)
P-value
Infectious episodes 28 (70%) 20 (50%) 0.016*
Pneumonia 11 (39.3%) 7 (35%) 0.039*
Surgical wound infection 3 (10.7%) 2 (10%) 0.876
Septic shock and sepsis 4 (14.3%) 3 (15%) 0.778
Urinary infection 5 (17.9%) 5 (25%) 1.000
Intravenous catheter
infection
5 (17.9%) 3 (15%) 0.543
* p-Value < 0.05 significant difference.
Table 5 Secondary outcomes.
Group (C)
(n= 40)
Group (AG)
(n= 40)
P-value
ICU LOS (days) 10.43 ± 4.67 7.81 ± 2.98 0.033*
Hospital LOS (days) 35.11 ± 1444 31.62 ± 11.47 0.235
Mortality 5 (12.5%) 4 (10%) 0.855
LOS: length of stay.
* P value < 0.05 significant difference.
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3.1. Primary outcome
The hyperglycemic episodes were significantly less in AG
group compared to C group. They were reported to occur in
29 AG group patients and in 38 in control group patients (P
value < 0.05). Hyperglycemia requiring insulin therapy in
AG group was significantly less (22 vs 28 patients)
(P< 0.05). Also those who required decreasing TPN require-
ments were significantly less in the AG group (7 vs 11 patients).
Insulin requirements per day in the AG group were signifi-
cantly lower (53 ± 11 vs 78 ± 9 IU) (Table 3). No with-
drawals were reported throughout the study period of 9 days.
Regarding secondary outcomes, each nosocomial episode
corresponds to a single patient. Patient can have more than
one episode of infection. The number of episodes of nosoco-
mial infection was lower in the AG group than in the control
group (P value < 0.05). The decrease in nosocomial infections
in patients receiving AG was related mainly to a decrease in
the incidence of pneumonia (Table 4; P< 0.05), whereas no
significant differences were found among the two groups
regarding the other types of nosocomial infections (surgical
wound infection, septic shock and sepsis, urinary tract infec-
tion, intravenous catheter infection). Three patients in the
AG group and seven patients in the control group had two dif-
ferent types of infectious episodes, such as pneumonia and
wound infection or pneumonia and septic shock.
There was significant difference between the two groups in
ICU length of stay (LOS), as it was significantly lower in the
AG group than the in control group (7.81 ± 2.98 vs 10.43
± 4.67 days), but the hospital LOS and 6 month mortality
rates showed no significant difference between the two groups
(Table 5). All patients completed the study period and mortal-
ities occurred after 9 days in both groups. Although there was
no significant difference between the two groups in mortalityrates, deaths due to infection were more in control group (four
patients) compared to the AG group (one patient).
4. Discussion
In this prospective controlled randomized study, AG dipeptide
supplemented TPN decreased incidence of hyperglycemia,
hyperglycemic episodes, insulin requirements, infectious epi-
sodes and ICU stay in diabetic patients who had LD liver
transplantation.
AG is a non-essential or conditionally essential amino acid
that plays an important role in maintaining and promoting the
function of many cells and tissues. AG enhances glucose-
stimulated insulin secretion via the metabolism of the
gamma-glutamyl cycle, glutathione synthesis and mitochon-
drial function [5]. It is known that AG modulates the glucose
induced loss of maximal insulin responsiveness [15]. AG,
together with insulin and glucose, increases the activity and
mRNA levels of pyruvate kinase involved in glucose metabo-
lism [16]. Experimental data on overweight hyperglycemic
mice showed that AG supplementation decreased weight gain,
hyperglycemia, and hyperinsulinemia but the actual mecha-
nism is still unknown [17]. Another animal study hypothesized
that AG needed ß cell depolarization and intracellular calcium
to act as a signaling molecule in amino acid and glucose stim-
ulated insulin secretion [18].
In a clinical study on type 2 diabetes patients who were
given oral AG supplementation, AG increased circulating
glucagon-like peptide 1 (GLP-1), glucose dependent insulin-
tropic polypeptide, and insulin concentration [19]. An experi-
mental study showed that insulin and AG attenuate the expres-
sion of inflammatory cytokines such as tumor necrosis factor-a
and interleukin-8, and reduce the oxidative stress of hyper-
glycemia concentration [20]. Our study showed that AG sup-
plementation decreased total insulin requirements per day
with a decrease in hyperglycemic episodes indicating a better
control of diabetes and thus decreasing insulin resistance
commonly seen in stressful conditions as in postoperative peri-
ods. This is consistent with a study done by De´chelotte et al.
on critically ill patients stating that AG by decreasing
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ity [21]. Also it was found that administration of AG attenu-
ates insulin resistance in trauma patients [22].
In the present study, administration of AG was associated
with less infectious episodes. This reduction is mainly due to
a decrease in incidence of pneumonia only and without any
significant reduction in other types of infectious episodes
between the two groups. These results are in accordance with
the decrease in infectious events when AG-enriched enteral
nutrition was supplemented to trauma patients [23] and par-
enterally supplemented to enterally feed severely burned
patients [24] and critically ill patients [21] and in patients with
peritonitis [25]. Also in another meta-analysis [26], AG
decreased risk of infection episodes. In contrast, Griffiths
et al. [27] observed no significant reduction in infectious epi-
sodes in critically ill patients receiving AG supplementation
but reported that there were reduced severity scores and ICU
death rates among the AG supplemented group stating that
parenteral nutrition containing glutamine may not reduce the
overall incidence of ICU acquired infection, but it may reduce
the risk of dying from acquired infections. The improved sur-
vival seen at 6 month appeared related mostly to reduced mor-
tality in the intensive care unit from multiple organ failure in
those patients in whom acquired infections are common.
In the current study, there was no significant difference
between the two groups in mortality rates but deaths were
caused by infectious vs non-infectious complications in (four
vs one respectively) patients in the control group, whereas an
opposite pattern (one vs three) was observed in the AG-
treated group suggesting that AG supplementation may reduce
the severity of infectious episodes which is in accordance with
other studies [21,27]. Other studies revealed a decrease in mor-
tality rates among AG supplemented groups [24,28,29] or a
trend toward reduction [30]. As infection is one of the leading
causes of morbidity and mortality in liver transplant recipients
and the release of cytokines during the infection can have other
indirect and negative effects, including allograft injury, oppor-
tunistic super-infection, and malignancy especially during the
first month immediately after transplantation [31], this may
be attributed to the recipients’ general poor preoperative clin-
ical condition, immunosuppressive therapy, the extensive sur-
gical field, and lengthy operating times, so that postoperative
respiratory disorders are very common after liver transplanta-
tion and significantly contribute to the related morbidity and
mortality, both in the acute postoperative stage and in the long
term course. AG supplementations seem beneficial to be used
in liver transplanted patients to decrease the rate of infection
especially pneumonia which was common in liver transplanted
patients as Pirat et al. [31] reported an incidence of 22.7% and
a mortality rate of 40% and Xia et al. [32] showed that the
overall incidence of severe pneumonia was 18.2%, with an
associated mortality rate of 37.5%. These authors found that
individuals who developed pneumonia had longer times to
extubation and higher mortality.
In the present study, AG enriched TPN had a significant
effect on the ICU LOS but not on hospital LOS which is
mainly attributed to the decreased incidence of infectious epi-
sodes and better control of diabetes in liver transplanted
patients. The difference in the hospital LOS among the two
groups in our study reflects the multi-factorial determinants
of LOS in hospitals among which infection is only one aspect.This was not in accordance with other studies done on criti-
cally ill patients which showed no significant effect on both
the ICU and the hospital LOS [21,28].
Other explanation for improved clinical outcome may be
due to other mechanisms that explain the effects of AG by
its influence on intestinal and immune function as it decreases
intestinal permeability in stressed patients [33–35]. Experimen-
tal studies reported that AG modulates inflammatory cytokine
production by gut mucosa, decreases pro-inflammatory cytoki-
nes such as interleukin 8 [36,37] or increases anti-inflammatory
cytokines such as interleukin 10 [38,39]. In addition, AG main-
tained intestinal and pulmonary IgA levels in rats [37,38]. AG
also modulates heat-shock protein expression [39,40] and
improves intestinal protein metabolism [41,42]. In addition,
AG maintains or restores immune defenses [43–45]. As this
study was designed to show the effect of using AG supplemen-
tation for 9 days on control of diabetes in liver transplanted
patients, Hb A1C was not assessed.
5. Conclusion
Our study showed that using AG supplementation in liver
transplanted patients who either have a history of diabetes
or NODM, reduces the insulin requirements, hyperglycemic
episodes, infectious events and ICU stay.
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